These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 38372058)

  • 21. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.
    Blakely CM; Weder W; Bubendorf L; He J; Majem M; Shyr Y; Chaft JE
    Lung Cancer; 2023 Mar; 177():59-72. PubMed ID: 36736076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
    Chen LN; Wei AZ; Shu CA
    Ther Adv Med Oncol; 2023; 15():17588359231163798. PubMed ID: 37007633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
    Saw SP; Ang MK; Tan DS
    Curr Treat Options Oncol; 2022 Dec; 23(12):1721-1731. PubMed ID: 36451063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
    Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
    J Thorac Cardiovasc Surg; 2024 Oct; 168(4):1245-1258.e17. PubMed ID: 38342430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
    Marinelli D; Gallina FT; Pannunzio S; Di Civita MA; Torchia A; Giusti R; Gelibter AJ; Roberto M; Verrico M; Melis E; Tajè R; Cecere FL; Landi L; Nisticò P; Porciello N; Occhipinti M; Brambilla M; Forde PM; Liu SV; Botticelli A; Novello S; Ciliberto G; Cortesi E; Facciolo F; Cappuzzo F; Santini D
    Crit Rev Oncol Hematol; 2023 Dec; 192():104190. PubMed ID: 37871779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials.
    Meng Y; Zhang Q; Wu R; Li H; Wang Z; Yao Y; Li X; Chen Z; Gong Y; Liu H
    Ther Adv Med Oncol; 2024; 16():17588359241284929. PubMed ID: 39376583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
    Leonetti A; Minari R; Boni L; Gnetti L; Verzè M; Ventura L; Musini L; Tognetto M; Tiseo M
    Clin Lung Cancer; 2021 Sep; 22(5):473-477. PubMed ID: 33762169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
    Han Y; Xiao X; Qin T; Yao S; Liu X; Feng Y; Li Z; Li Y; Xia S
    Cancer Immunol Immunother; 2024 Oct; 73(12):262. PubMed ID: 39382658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials.
    Yu A; Fu F; Li X; Wu M; Yu M; Zhang W
    Front Oncol; 2024; 14():1351359. PubMed ID: 38454928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
    Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
    Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer.
    Martins RS; Razi SS; Alnajar A; Poulikidis K; Latif MJ; Luo J; Bhora FY
    Ann Thorac Surg; 2024 Sep; 118(3):672-681. PubMed ID: 38290596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
    Huang H; Li L; Tong L; Luo H; Luo H; Zhang Q
    PLoS One; 2024; 19(9):e0310808. PubMed ID: 39312569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative adjuvant therapy for resectable early non-small cell lung cancer: A protocol for a systematic review and meta-analysis.
    Chai T; Zhang P; Lin Y; Zhang Z; Lin W; Kang M; Lin J
    Medicine (Baltimore); 2019 Jul; 98(30):e16468. PubMed ID: 31348250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC.
    Brazel D; Nagasaka M
    Med; 2024 Aug; 5(8):852-855. PubMed ID: 39127033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.